[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,43,70,106,127,160,207,233,261,280,306,333,356,386,418,457,495],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644342","flyte-device-for-improving-urinary-incontinence-among-endometrial-and-cervical-cancer-survivors-who-have-undergone-radiation-therapy-100644342",false,"NCT07662824","Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy","Flyte System Transvaginal Mechanotherapy for Urinary Incontinence in Endometrial and Cervical Cancer Survivors: A Pilot Study","Inclusion Criteria:\n\n* Female patients who have received conventionally fractioned adjuvant or primary pelvic radiation therapy for endometrial or cervical cancer ≥ 3 months prior to registration\n* Age ≥ 21 years at enrollment\n* English speaking\n* Demonstrates understanding of the study protocol and has signed the Informed Consent Form (ICF)\n* Has a clinical diagnosis of urinary incontinence (stress urinary incontinence \\[SUI\\], urge urinary incontinence \\[UUI\\], mixed) or overactive bladder (OAB)\n* Ability to contract the pelvic floor muscles (PFMs) without pain\n* Ability to tolerate size 6 vaginal dilator\n* Internet access\n* Access to an iOS or Android smartphone or tablet with capabilities to download and use the Flyte app\n* Willing and able to participate in follow-up\n\nExclusion Criteria:\n\n* Participation in another clinical study which may interfere with study requirements\n* Currently receiving active cancer directed therapy (i.e., cytotoxic chemotherapy) in post hysterectomy patients\n* Completion of radiation therapy or surgery within 3 months of enrollment\n* Life expectancy is less than six months in the opinion of the investigator\n* Inability to tolerate insertion of the intravaginal wand. This will be recorded to support the usability of Flyte secondary endpoint\n* Suspected vesicovaginal or colovaginal fistula\n* Physical limitations that impede the patient's ability to participate (e.g., ability to grasp the wand and insert it and ability to turn on the Flyte controller unit)\n* Acute infection or hematuria\n* Inability to contract the PFMs or pain with contraction, as confirmed with intravaginal exam\n* Impaired cognitive function or neurologic conditions","FEMALE","21 Years",{"count":19,"type":20},44,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial studies how well and how easy it is to use a device called Flyte in improving problems with bladder control (urinary incontinence) among endometrial and cervical cancer survivors who have undergone radiation therapy. Urinary incontinence is common after pelvic radiation therapy and can affect daily life and well-being. Access to in-person pelvic floor physical therapy can be limited. The Flyte device is designed for in-home use to deliver a series of mechanical vibrations at a specific frequency while the pelvic floor muscles are contracting and relaxing (i.e., normal, guided Kegel exercises). This treatment is called mechanotherapy. The Flyte device may improve urinary incontinence symptoms, as well as overall quality of life among endometrial and cervical cancer survivors who have undergone radiation therapy.",[26,27,28,29],"Cervical Carcinoma","Endometrial Carcinoma","Overactive Bladder","Voiding Disorders","NOT_YET_RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":20},"2026-08-13",{"date":38,"type":20},"2028-08-13",{"name":40,"class":41},"Mayo Clinic","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100614579","self-collection-for-hpv-testing-to-improve-cervical-cancer-prevention-ship-trial-lmi-001-a-s04-100614579","NCT07281430","Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)","NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial LMI-001-A-S04","Inclusion Criteria:\n\n* Willingness and ability to provide a documented informed consent\n* Is 25 years or older\n* Has an intact cervix\n* Has had a referral for colposcopy in which routine cervical cancer screening has included positive HPV testing (HPV primary screening, co-testing, or atypical squamous cells of undetermined significance \\[ASC-US\\] cytology triage) or abnormal cytology performed within the past 12 months preceding the referral visit, and\u002For for cervical excisional procedure\n* Willing and able to undergo colposcopy, and if clinically indicated for SOC purposes, a biopsy, endocervical curettage, and\u002For a cervical excisional procedure, as applicable\n\nExclusion Criteria:\n\n* Is pregnant when presenting for the referral visit or gave birth within the past 3 months\n* Has a known history of excisional or ablative therapy to the cervix (e.g., loop electrosurgical excision procedure \\[LEEP\\], cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the referral visit\n* Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records\n* Known medical conditions that, in the opinion of the investigator, preclude study participation\n* Previous participation in the SHIP Trial or another cervical cancer screening study within the past 12 months. Participation is defined as completing the self-collection\n* Is experiencing unusual bleeding or pelvic pain",true,"25 Years",{"count":53,"type":20},500,[23],"This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and\u002For cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. HPV is known to cause a variety of cancers including cervical cancer. Even though there are ways to detect cervical cancer, many individuals are not diagnosed. Over half of all new cervical cancer cases are among those who have either never been screened or who are not screened enough. The low screening numbers show more testing needs to be done. Without appropriate screening and care, preventable precancer may turn into cancer. A new way to detect cervical cancer is to have individuals collect their own sample for HPV testing to know their risk for cervical cancer. This may give individuals more flexibility and comfort having the ability to collect samples themselves, compared to a doctor performing a speculum examination and collecting the samples in a clinic. Information gathered from this study compares clinical accuracy of HPV testing on self-collected vaginal samples versus cervical samples collected by clinician.\n\nThe Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial is part of the National Cancer Institute (NCI)'s Cervical Cancer 'Last Mile' Initiative, a public private partnership that seeks to increase access to cervical cancer screening. The SHIP Trial focuses on developing clinical evidence to inform the US Food and Drug Administration (FDA)'s regulatory reviews of self-collection approaches as alternative sample collection approaches for cervical cancer screening. Several industry partner-specific self-collection device and assay combinations will be non-competitively and independently evaluated with a similar study design framework to inform pre-approval and\u002For post-approval regulatory requirements.",[26,57],"Human Papillomavirus Infection","RECRUITING","2026-06-16",{"date":61,"type":34},"2026-06-17",{"date":63,"type":34},"2025-11-24",{"date":65,"type":20},"2026-12-31",{"name":67,"class":68},"National Cancer Institute (NCI)","NIH",18,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":77,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":93,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":42},"100590480","research-of-double-positive-circulating-cells-tumor-marker--cd45-in-several-types-of-metastatic-cancers-100590480","NCT06967961","Research of Double-positive Circulating Cells (Tumor Marker \u002F CD45+) in Several Types of Metastatic Cancers","DP-PAN-CANCER","Inclusion Criteria:\n\n* 1\\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors\n* 2\\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet\n* 3\\. Age ≥ 18 years\n* 4\\. Patient affiliated to a French Social Security scheme\n* 5\\. Patient having signed his\u002Fher informed consent prior to inclusion in the study and prior to any specific procedure for the study.\n\nExclusion Criteria:\n\n* 1\\. Patient with localized disease.\n* 2\\. Pregnant or breast-feeding women.\n* 3\\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and\u002For procedures set out in the study protocol.\n* 4\\. Patient who has forfeited his\u002Fher freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).","ALL","18 Years",{"count":80,"type":20},450,[23],"A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis.\n\nEach patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.\n\n450 patients will be enrolled in total.",[84,85,86,87,88,89,90,91,92,26],"Urothelial Carcinoma","Renal Cancer","Prostate Adenocarcinoma","Adenocarcinoma of Endometrium","Cutaneous Melanoma","Soft Tissue Sarcoma (STS)","Nonseminomatous Germ Cell Tumor","Seminomatous Germ Cell Tumor","Upper Aerodigestive Tract Carcinoma",[94,95,96],"metastatic cancers","Double Positive Circulating cells","liquid biopsy","2026-06-12",{"date":99,"type":34},"2026-06-15",{"date":101,"type":34},"2025-07-23",{"date":103,"type":20},"2029-07-23",{"name":105,"class":41},"Institut Claudius Regaud",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":42},"100641774","phase-1-neoadjuvant-lymph-node-targeted-immunotherapy-in-cervical-cancer-a-feasibility-study-neolync-100641774","NCT07653503","Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)","NEOLYNC","Inclusion Criteria:\n\n* Female participants with uterus and cervix in situ who are at least 18 years of age on the day of signing informed consent with histologically confirmed primary diagnosis of cervical cancer and are intended to be treated with standard-of-care surgery (\\\u003C FIGO IB3). Only female participants with reproductive organs still in situ are eligible because this ensures the highest chance of the correct lymph(node) anatomy needed for the administration of the IMP;\n* The participant is not pregnant, not breastfeeding, is not a woman of childbearing potential (WOCBP) or agrees to follow contraceptive guidance as described in 9.2.1. during the treatment period and at least until SoC surgery;\n* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n\nExclusion Criteria:\n\n* WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks \\[could consider shorter interval for kinase inhibitors or other short half-life drugs\\] prior to allocation.\n* Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.\n* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (defined as \\>10 mg prednisone equivalent per day) or other systemic immunosuppressive therapy within 7 days prior to the first dose of study drug. The use of systemic corticosteroids and other immunosuppressants prior to initiation of study treatment should be avoided due to potential interference with the pharmacodynamic activity of nivolumab. Use of immunosuppressive agents after initiation of treatment is allowed when clinically indicated for the management of immune-related adverse events.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n* Has known active CNS metastases and\u002For carcinomatous meningitis.\n* Has severe hypersensitivity (≥Grade 3) to nivolumab and\u002For any of its excipients.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Any contraindication to MRI, including but not limited to the presence of non-MRI-compatible implants (e.g., pacemakers, cochlear implants, neurostimulators), ferromagnetic metal fragments, or severe claustrophobia unmanageable with standard precautions.\n* Prior surgical intervention in the inguinal region with potential disruption of lymphatic drainage.\n* Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authority.\n* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n* Any condition, as assessed by the research physician and\u002For medical oncologist, that in their clinical judgment makes the patient unsuitable for participation in the study. This may include, but is not limited to, poor physical condition, abnormal laboratory values, or other medical or psychosocial factors that could compromise patient safety or study integrity. Patients that are excluded based on this criterium will always be reported to the DSMB.",{"count":114,"type":20},12,[116],"PHASE1","We aim to determine feasibility, safety and efficacy of TDLN-targeted immune checkpoint inhibition in different doses (nivolumab) in patients with cervical cancer.",[26],"2026-06-11",{"date":61,"type":34},{"date":122,"type":34},"2026-01-05",{"date":124,"type":20},"2027-12-01",{"name":126,"class":41},"University Medical Center Groningen",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},"100483906","phase-3-para-aortic-lymphadenectomy-in-locally-advanced-cervical-cancer-100483906","NCT05581121","PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer","PAROLA","Inclusion Criteria:\n\n1. Age ≥ 18 years at time of study entry\n2. Newly diagnosed histologically proven cervical squamous carcinoma, adenocarcinoma, or adenosquamous tumor\n3. FIGO stage IIIC1 (FIGO 2018) cervical cancer with FDG-PET\u002FCT showing FDG-positive pelvic nodes and FDG-negative PALN including equivocal lymph nodes in the common iliac and para-aortic regions. The highest positive lymph node must be located inferior to the common iliac bifurcation in both sides (anatomical level 1).\n4. Patients with TNM T stage I-IIIB.\n5. FIGO stage IIIC1 cervical cancer by positive pelvic sentinel lymph node from surgical staging (either intraoperative assessment (frozen section) or from final histology - patients are not eligible after radical hysterectomy, and FDG-negative common iliac of para-aortic lymph node on PET\u002FCT (performed before or after SLN procedure)\n6. Patient eligible for pelvic radiotherapy and cisplatin-based chemotherapy with a curative intent as confirmed by a multidisciplinary board\n7. ECOG performance status \\\u003C 2 i.e. 0 or 1\n8. Life expectancy more than 12 months\n9. Pretherapeutic imaging FDG-PET\u002FCT images should be available for central review\n10. Prior validation of the surgeon's participation in the study by the Quality Assurance Comity\n11. Women should be post-menopaused or willing to accept the use of an effective contraceptive regimen during the treatment period. All non-menopaused women should have a negative pregnancy test within 72 hours prior to study entry.\n12. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up\n13. Not applicable since protocol revision V4. Patient participating to other clinical trials including immunotherapy strategies or adjuvant chemotherapy is also eligible for the study. Adjuvant treatment must be decided prior to randomization\n14. Signed informed consent\n15. Patient affiliated to a Social Health Insurance in France (French patients only).\n\nExclusion Criteria:\n\n1. Unequivocal positive common iliac or para-aortic lymph nodes at pretherapeutic imaging FDG-PET\u002FCT\n2. Negative or equivocal pelvic lymph nodes at pretherapeutic imaging FDG-PET\u002FCT\n3. Metastatic disease confirmed by FDG-PET\u002FCT\n4. Other histologies than adenocarcinoma, squamous cell carcinoma and adenosquamous carcinoma\n5. Contraindication for cisplatin-based chemotherapy\n6. Women who received any prior treatment for cervical cancer\n7. Prior surgery for the cervical cancer, except for cone procedure and pelvic lymph node staging\n8. Previous pelvic radiotherapy\n9. History of another primary malignancy except for: Malignancy treated with curative intent and with no known active disease after 5 years, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated carcinoma in situ (any location) without evidence of disease.\n10. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure\n11. Patient who has forfeited his\u002Fher freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).",{"count":135,"type":20},510,[137],"PHASE3","This is an international, multicenter and randomized open-label phase III study designed to demonstrate, in patients with stage IIIC1 cervical cancer, whether para-aortic lymphadenectomy followed by tailored chemoradiation is associated with increased disease-free survival compared to patients staged with FDG-PET\u002FCT only followed by chemoradiation.\n\nThe planned sample size is 510; including 200 patients in France.\n\nIn this trial, patients will be assigned in one of the two following treatments arms:\n\n* Arm A (control arm): Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO\u002FESTRO recommendations.\n* Arm B (experimental arm): Pretherapeutic para-aortic lymphadenectomy followed by tailored chemo-radiotherapy and brachytherapy.\n\nConsidering the changing standard treatment landscape of locally advanced cervical cancer, both arms (control arm and experimental arm) may also be treated according to the INTERLACE and KEYNOTE-A18 studies, if applicable, at the discretion of the attending physician.\n\nEach patient will be followed up for 5 years.\n\nA cost-utility study will be performed in patients included in France. Other countries could be involved in this specific study. It will assess the incremental cost-utility ratio (cost per QALY gained) of para-aortic lymphadenectomy followed by tailored chemo-radiation in patients with positive PALN compared to patients staged with PET\u002FCT only followed by chemo-radiation.\n\nThis study also has ancillary objectives:\n\n* Biologic: To study T cell exhaustion, immune changes during chemoradiation, HPV ctDNA dynamic evolution, and the par-aortic lymph node as a premetastatic niche.\n* Radiomics: To study the contribution of radiomics and FDG-PET\u002FCT metabolic parameters to predict para-aortic lymph node involvement and clinical outcome.\n* Senti-PAROLA: To evaluate the accuracy (Sensitivity, specificity, positive and negative predictive value) of the para-aortic sentinel lymph node (SPA) for PALN staging, and to evaluate the prognostic value of low volume metastasis of SPA.",[26,140,141],"Adenocarcinoma","Adenosquamous Carcinoma",[143,144,145,146,147,148,149,150],"Locally advanced cervical cancer","HPV 16+","Stage IIIC1","Radiation therapy","Cisplatin","Para-aortic lymphadenectomy","INTERLACE","KEYNOTE-A18","2026-05-21",{"date":153,"type":34},"2026-05-26",{"date":155,"type":34},"2023-12-20",{"date":157,"type":20},"2033-12-20",{"name":105,"class":41},35,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":77,"minAge":78,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":42},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":168,"type":20},27,[170],"PHASE2","This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[173,174,175,176,177,26,178,27,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,84],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Bladder Carcinoma","Breast Carcinoma","Colorectal Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Hodgkin Lymphoma","Lung Carcinoma","Malignant Solid Neoplasm","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Ovarian Carcinoma","Pancreatic Carcinoma","Primary Peritoneal Carcinoma","Prostate Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","2026-05-15",{"date":201,"type":34},"2026-05-18",{"date":203,"type":34},"2025-12-18",{"date":205,"type":20},"2026-12-18",{"name":40,"class":41},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":214,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":231,"locationsCount":42},"100624285","phase-2-vaginal-dhea-to-improve-vaginal-health-after-radiation-for-women-with-gynecologic-anal-or-rectal-cancer-100624285","NCT07407647","Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer","Vaginal DHEA for Women With Gynecologic and Gastrointestinal Cancer After Radiation","Inclusion Criteria:\n\n* Any patient with anal, rectal, cervical, vaginal, or vulvar cancer receiving external beam radiation alone, or both external beam radiation and brachytherapy with curative intent (Participants will be consented and enrolled prior to starting treatment but will not receive intervention till after treatment is completed)\n* Concurrent or prior chemotherapy is allowed\n* Any prior gynecologic surgery is permitted\n* Rectal surgery, including lower anterior resection and abdominoperineal resection, is permitted\n* Subject must be menopausal, which is defined as age \\> 50 with no menses for 12 months or bilateral oophorectomy\n\nExclusion Criteria:\n\n* Patients with scleroderma, mixed connective tissue disorder, and lupus will be excluded\n* Patients who have received prior pelvic radiation\n* Undiagnosed abnormal genital bleeding (unrelated to current diagnosis or treatment related toxicity)\n* Endometrial cancer or endometrial hyperplasia\n* Use of estrogen alone injectable or progestin implant therapy with 3 months before study entry\n* Use of estrogen pellet or progestin injectable drug within 6 months before study entry\n* Use of oral estrogen, progestin, or DHEA or intrauterine progestin within 8 weeks before study entry\n* Use of vaginal estrogen (rings, creams, tablets, or gels), transdermal estrogen +\u002F- progestin, vaginal hyaluronic acid, or pro-estrogenic herbal treatments such as black cohosh in the 4 weeks before study entry. Intravaginal moisturizers and lubricants prior to enrollment are permitted\n* History of breast cancer\n* Patients receiving palliative radiation therapy\n* Patients who do not meet criteria for menopause","50 Years",{"count":216,"type":20},25,[170],"This phase II trial tests the feasibility and side effects of vaginal DHEA to improve vaginal health after radiation for women with gynecologic, anal or rectal cancer. Treatment of cancers with radiation to the abdomen can influence the vaginal microbiome (any bacteria, virus, or other organisms found in the vagina). Both menopause and radiation cause a decrease in lubrication and elasticity of the vagina and symptoms including vaginal dryness, vaginal burning and itching, vaginal bleeding, pain or burning during urination, and pain during sexual intercourse. DHEA is a type of hormone replacement therapy. It is use to improve symptoms in women during menopause and may be effective in treating these symptoms for women who have received radiation.",[220,26,221,222,223,224],"Anal Carcinoma","Malignant Female Reproductive System Neoplasm","Rectal Carcinoma","Vaginal Carcinoma","Vulvar Carcinoma","2026-04-16",{"date":227,"type":34},"2026-04-21",{"date":229,"type":34},"2026-03-12",{"date":65,"type":20},{"name":232,"class":41},"Ohio State University Comprehensive Cancer Center",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":42},"100577887","systemic-and-tumor-immune-response-during-pelvic-chemoradiation-andor-brachytherapy-for-cervical-cancer-100577887","NCT06804135","Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and\u002For Brachytherapy for Cervical Cancer","Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and\u002For Brachytherapy for Cervical Cancer (STIRR Cervix Study)","STIRR","Inclusion Criteria:\n\n* Common Inclusion Criteria:\n\n  1. Age 18 years and above.\n  2. Ability to tolerate full course of pelvic radiotherapy+\u002F- chemotherapy +\u002F- brachytherapy.\n  3. Ability to understand and willingness to sign an informed consent document.\n  4. Should be willing to undergo extra biopsies and blood samples collection for translational research study.\n\nCohort A:\n\n1. Patients diagnosed with LACC Stage IB2 - IIIC1, as per FIGO 2018 Classification for Radical Cohort.\n2. Stage IIIB-IVA where palliative RT is indicated for palliative cohort.\n3. No previous irradiation to the pelvis or chemo therapy.\n\nCohort B:\n\n1. Patients diagnosed with LACC Stage IIIC2, as per FIGO 2018 Classification.\n2. No previous irradiation to the pelvis or chemotherapy.\n\nCohort C:\n\n1. Patients diagnosed with gynecological cancer and presenting with need of infield radiation.\n2. Planned for reirradiation.\n\nExclusion Criteria:\n\n1. Severe medical condition impairing complete treatment delivery.\n2. Patients with immunocompromised states or active infection.\n3. Patients on immunosuppressive drugs for other medical conditions.\n4. Patients who will receive immune checkpoint inhibition (ICI) therapy.",{"count":242,"type":20},110,"OBSERVATIONAL","Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression. Thus the investigators hypothesize that pelvic and\u002For para-aortic radiotherapy for cervical cancer affects local tumor immunity as well as systemic immune response that may be instrumental for long term cancer cure. The goal of this observational study is to understand the effect of various radiotherapy dose per fraction, total dose and field volumes of radiation on systemic and tumor immune response in cervical cancer. The outcome of the study would be useful in improving the quality of radiation treatment and in reducing disease recurrence and improving survival in patients with cervical cancer.",[26],[247,248,249,250],"Cervical Cancer","Immune System","Radiotherapy","PD-L1 Expression","2026-02-03",{"date":253,"type":34},"2026-02-04",{"date":255,"type":34},"2025-10-25",{"date":257,"type":20},"2030-01-30",{"name":259,"class":260},"Tata Memorial Hospital","OTHER_GOV",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":50,"sex":77,"minAge":4,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":21,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":42},"100567284","the-ohio-state-university-osu-screen-community-program-100567284","NCT06666192","The Ohio State University (OSU) SCREEN Community Program","A Multi-Level Intervention for Improving Screening Rates of Breast, Cervical and Colorectal Cancer in Women in Low-Income Communities","Inclusion Criteria:\n\n* Level 1 is the health clinics (Helping Hands \\[pilot\\]; 6 Lower Lights clinics). Clinics are eligible if they provide preventive health care to residents of the targeted census tracts.\n* Level 2 focuses on health care providers (physicians, nurses, physician assistants \\[PA\\]\u002Fnurse practitioners \\[NPs\\]) and office staff practicing at participating clinics who are involved in the screening and\u002For screening referral process (determined by individual clinical sites) and can speak, read, and write English\n* Patients (Level 3) are the recipients of health care and screening interventional strategies implemented by clinics and providers.\n* Level 4 is the community to include residents in targeted census tracts around each clinic.",{"count":269,"type":20},2067,[23],"This clinical trial develops and tests how well a multi-level intervention (MLI), The Ohio State University (OSU) SCREEN Community Program, works to increase screening and follow-up for breast, cervical and colorectal (CRC) cancer among low-income and un\u002Funderinsured female residents in three counties in Central Ohio. In Ohio, incidence and mortality rates for breast, cervical and CRC are higher than or similar to the national average; in addition, underserved populations - minority, rural and low-income women - have higher rates of these cancers. Screening can detect precancerous colorectal and cervical lesions and other early-stage cancers when treatment is less intensive and more successful and is known to reduce mortality rates for breast, cervical, and CRC, however many of these women lack access to health care and screenings. This MLI includes clinic-based components, such as patient education, as well as community-based strategies, such as media programs and training health workers, that can increase rates of guideline-recommended breast, cervical and CRC screening and follow-ups in underserved populations. The OSU SCREEN Community Program may be an effective way to improve breast, cervical and CRC screenings among underserved women in Ohio.",[177,26,178],{"date":274,"type":34},"2025-12-24",{"date":276,"type":34},"2024-03-12",{"date":278,"type":20},"2029-12-31",{"name":232,"class":41},{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":289,"conditions":290,"keywords":293,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":305},"100613529","contribution-of-oncovascular-surgery-in-the-treatment-of-gynecological-advanced-malignant-diseases-100613529","NCT07267780","Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.","The Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases: a Prospective and Retrospective Multicenter Study","Inclusion Criteria:\n\n\\- Retrospective Arm:\n\n1. Diagnosis of advanced or recurrent gynecologic cancer with vascular involvement requiring resection and\u002For reconstruction of major blood vessels, including:\n\n   * Ovarian carcinoma\n   * Cervical carcinoma\n   * Endometrial carcinoma\n   * Vulvar carcinoma\n   * Uterine or other types of sarcomas with vascular involvement\n2. Documented major vascular invasion, confirmed by preoperative imaging or intraoperative description.\n3. Patients who underwent onco-vascular surgery for advanced or recurrent gynecologic cancers between January 1, 2017, and August 31, 2025.\n4. Data Protection Impact Assessment (DPIA) approved for the management of retrospective data. (Deceased or untraceable patients will also be included to avoid selection bias, in accordance with Article 110 bis, paragraph 4 of the Italian Privacy Code. A DPIA will be produced and published on the Sponsor's website before study initiation, and patients who explicitly objected before death will not be included.)\n\nProspective Arm:\n\n1. Age ≥18 years\n2. Patients eligible for onco-vascular surgery for advanced or recurrent gynecologic cancers with vascular involvement, including:\n\n   * Ovarian carcinoma\n   * Cervical carcinoma\n   * Endometrial carcinoma\n   * Vulvar carcinoma\n   * Uterine or other types of sarcomas\n3. Documented major vascular invasion, confirmed by preoperative imaging or intraoperative description.\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Patients younger than 18 years of age\n2. Patients with early-stage gynecologic cancers not eligible for onco-vascular surgery\n3. Patients undergoing vascular resection due to accidental injury of blood vessels not directly related to tumor infiltration.\n4. Patients who have previously undergone vascular surgery for reasons unrelated to the study, to avoid data overlap.",{"count":288,"type":20},130,"Multicenter ambispective observational study (prospective\u002Fretrospective)",[193,26,27,224,291,292],"Uterine Sarcoma","Gynecologic Tumor",[294,295],"Advanced or recurrent gynecologic tumor","Vascular infiltration","2025-11-25",{"date":298,"type":34},"2025-12-05",{"date":300,"type":20},"2025-12",{"date":302,"type":20},"2035-12",{"name":304,"class":41},"National Cancer Institute, Naples",2,{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":21,"phases":316,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":42},"100599764","phase-2-clinical-study-to-evaluate-the-efficacy-and-safety-of-nab-paclitaxel-combined-with-cisplatin-and-sintilimab-in-neoadjuvant-treatment-of-locally-advanced-cervical-cancer-100599764","NCT07088731","Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer","A Prospective, Single-Center, Randomized Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer","Inclusion Criteria:\n\n* Aged ≥ 18 years and ≤ 70 years;\n* Cervical cancer with pathological types being squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;\n* Staged IB3 or IIA2 according to the FIGO 2018 staging system, as assessed by the investigator;\n* ECOG performance status of 0-2, or KPS score ≥ 70;\n* Expected survival time of more than 3 months;\n* Having at least one measurable lesion in accordance with RECIST 1.1;\n* Laboratory test results meeting the following criteria without drug intervention:\n\n  1. Hemoglobin ≥ 90 g\u002Fdl, neutrophil count ≥ 1.5 × 10⁹\u002FL, platelet count ≥ 100 × 10⁹\u002FL;\n  2. Creatinine ≤ 1.5 times the upper limit of normal range;\n  3. Total bilirubin, alanine transaminase (ALT), and aspartate transaminase (AST) \\\u003C 2 times the upper limit of normal;\n* Postmenopausal, or reproductive-aged women who meet all the following conditions: non-lactating, not pregnant, and able to use effective contraceptive measures during the study treatment period;\n* Voluntarily participating in this study and signing the informed consent form.\n\nExclusion Criteria:\n\n* Participated in other clinical trials within 30 days before receiving the first dose of chemotherapy drugs or during the treatment period.\n* Previously received any other anti-tumor treatment for cervical cancer.\n* Non-HPV-related cervical cancer.\n* Needing to receive other anti-tumor treatments during the study treatment period.\n* Patients with known allergies to the active ingredients of the study drugs or their excipients.\n* Diagnosed with other malignant tumors in the past 5 years (except those judged to be cured by the investigator).\n* Active infections requiring systemic treatment.\n* Positive for human immunodeficiency virus (HIV) antibody.\n* Positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody.\n* Peripheral neuropathy with a grade of ≥ 2 according to the NCI-CTCAE (Version 5.0).\n* Concurrent diseases or abnormal test results that interfere with the subject's ability to receive anti-tumor treatment as judged by the investigator, such as the estimated inability of the subject to tolerate at least 2 cycles of neoadjuvant chemotherapy plus surgery or concurrent chemoradiotherapy, etc.\n\nParticipation in this study is deemed not conducive to the maximum benefit of the subject as judged by the investigator.","70 Years",{"count":315,"type":20},180,[170],"For locally advanced cervical cancer, there are two main treatment options:\n\nOne is radical chemoradiotherapy (a combination of radiotherapy and chemotherapy aimed at curing the disease).\n\nThe other is having neoadjuvant treatment first (treatment given before the main surgery to shrink the tumor) followed by radical surgery.\n\nSo far, there's no clear answer on which of these two options is better. In general, cervical cancer responds well to immunotherapy. But we still don't know for sure if adding immunotherapy to neoadjuvant chemotherapy can improve the treatment effect for locally advanced cervical cancer, or even make it better than radical chemoradiotherapy.\n\nThis study aims to compare the effects of two approaches: radical chemoradiotherapy versus neoadjuvant chemotherapy plus immunotherapy followed by surgery.",[26],[320,321,322,323],"locally advanced","neoadjuvent chemotherapy","neoadjuvent immunotherapy","CCRT","2025-09-17",{"date":326,"type":34},"2025-09-22",{"date":328,"type":20},"2025-09",{"date":330,"type":20},"2027-07",{"name":332,"class":41},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":21,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":355},"100553898","phase-2-cryocompression-with-or-without-cilostazol-for-the-prevention-of-paclitaxel-induced-neuropathy-in-patients-with-gynecological-cancers-100553898","NCT06492070","Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers","Prevention of Paclitaxel-Induced Peripheral Neuropathy: Randomized Trial of Cryocompression With or Without Cilostazol","Inclusion Criteria:\n\n* INCLUSION CRITERIA FOR ARMS A and B:\n* Age 18 years or older\n* Diagnosis of uterine, ovarian\u002Ffallopian tube\u002Fprimary peritoneal, cervical, or vulvar cancer and planned chemotherapy regimen of 6-9 cycles of paclitaxel and carboplatin or cisplatin with or without VEGF inhibition, with or without immunotherapy, and with or without HER2-directed therapy\n* Eastern Cooperative Oncology Group performance status from 0 to 2\n* ARM C: Age 18 years or older\n* ARM C: Diagnosis of uterine, ovarian\u002Ffallopian tube\u002Fprimary peritoneal, cervical, or vulvar cancer and completion of 6-9 cycles of a chemotherapy regimen consisting of paclitaxel and carboplatin or cisplatin with or without VEGF inhibition, with or without immunotherapy, and with or without HER2-directed therapy within the last 3 months\n* ARM C: Eastern Cooperative Oncology Group performance status from 0 to 2\n\nExclusion Criteria:\n\n* EXCLUSION CRITERIA FOR ARMS A and B:\n* Any patient unable and\u002For unwilling to cooperate with all study protocols\n* Previous treatment with paclitaxel\n* Patients with baseline pre-chemotherapy neuropathy requiring pharmacologic treatment\n* Diabetes mellitus with hemoglobin A1c \\>7.0\n* Hepatic impairment, moderate to severe (Class B \\& C by Child-Pugh score)\n\n  * Slight or moderate malignant ascites alone will not be considered indicative of hepatic impairment in the absence of other evidence of hepatic disease\n* Raynaud's phenomenon\n* Active wounds on the hands or feet\n* High risk uncontrolled arrhythmias\n* Ischemic heart disease\n* Inadequate bone marrow function with white blood count \\\u003C 4,000\u002Fmm\\^3 and platelet count \\\u003C 100,000\u002Fmm\\^3\n* Inadequate liver function with serum total bilirubin \\>= 1.5mg\u002FdL\n* Inadequate renal function with serum creatinine \\>= 1.5mg\u002FdL\n* On one or more antiplatelet therapies excluding acetylsalicylic acid\n* Hypersensitivity (e.g. anaphylaxis, angioedema) to cilostazol or any components of cilostazol\n* Pregnant and nursing patients\n\n  * Patients enrolled in this study who have the potential to become pregnant (have an intact uterus, ovary(ies), and fallopian tube(s), have not entered menopause, and have regular menses) are required to utilize reliable contraception such as celibacy, hormonal contraception (oral pills, implant, injection, ring or patch), intrauterine device (IUD), condom and\u002For diaphragm with spermicide\n* Incarcerated patients\n* Patients unable to consent for themselves, due to cognitive impairment or other reason\n* Patients with contraindications to cilostazol\n* Any patient who does not meet criteria to receive chemotherapy\n* ARM C: Any patient unable and\u002For unwilling to cooperate with all study protocols\n* ARM C: Previous treatment with paclitaxel\n* ARM C: Patients with baseline pre-chemotherapy neuropathy requiring pharmacologic treatment\n* ARM C: Diabetes mellitus with hemoglobin A1c \\>7.0\n* ARM C: Pregnant patients\n* ARM C: Incarcerated patients\n* ARM C: Patients unable to consent for themselves, due to cognitive impairment or other reason",{"count":341,"type":20},70,[170],"The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for patients with gynecologic cancers. Peripheral neuropathy is a common side effect of many chemotherapeutic agents, including paclitaxel. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Cryocompression is a therapy that combines compression garments or dressings with cooling of the treated area. Cilostazol is in a class of medications called platelet-aggregation inhibitors (antiplatelet medications). It works by improving blood flow to the legs. Giving cilostazol together with cryocompression may be safe and tolerable in treating patients with gynecological cancers.",[26,179,187,345,193,195,224],"Malignant Uterine Neoplasm","2025-08-20",{"date":348,"type":34},"2025-08-27",{"date":350,"type":34},"2024-08-01",{"date":352,"type":20},"2027-12-31",{"name":354,"class":41},"Emory University",3,{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":50,"sex":77,"minAge":363,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":367,"conditions":368,"keywords":373,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":305},"100595727","transmission-of-oncogenic-hpv-infection-among-families-100595727","NCT07036211","Transmission of Oncogenic HPV Infection Among Families","TREVINO","Inclusion Criteria:\n\n* Patient with colposcopy clinic detected persisting HR-HPV infection\n* Patient with diagnosed cervical cancer\n* Patient with diagnosed OSCC\n* Patients' sexual partners of women or men that are referred to the colposcopy\u002Fgynecological oncology\u002FENT\n* offspring (over 12 years old) of the referred couples\n\nExclusion Criteria:\n\n* Candidate who don't speak Finnish","12 Years","100 Years",{"count":366,"type":20},700,"The goal of the Transmission of Oncogenic HPV Infection Among Families (TREVINO) study is to improve understanding of how high-risk human papillomavirus (HPV) infections are transmitted within families. The research focuses on transmission between sexual partners and between parents and children. It also examines how the various microbes may influence the persistence of HPV infections and the development of HPV-related cancers.\n\nThe study will include up to 300 couples recruited from gynecology and ear, nose, and throat (ENT) clinics in Finland, as well as their children. Participants include individuals with persistent HPV infection, cervical precancer or cancer, or HPV-related head and neck cancer, along with their partners and potentially their offspring.\n\nParticipants will provide self-collected samples from the oral and genital areas at multiple time points over up to five years. Questionnaires addressing medical, behavioural, and environmental factors will be completed.\n\nThe study is conducted at Tampere University Hospital and Kuopio University Hospital in Finland. Results will inform HPV screening and prevention programs, improve understanding of family-level transmission, and identify potential microbial and genetic markers linked to cancer risk.",[369,26,370,371,372,57],"Human Papilloma Virus (HPV)","Oropharyngeal Carcinoma","Transmission Vertical","Transmission",[374,375,376],"Oropharyngeal cancer","Cervical cancer","HPV","2025-06-16",{"date":379,"type":34},"2025-06-25",{"date":381,"type":20},"2025-08",{"date":383,"type":20},"2031-12",{"name":385,"class":41},"Tampere University Hospital",{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":77,"minAge":78,"maxAge":4,"enrollmentInfo":393,"targetDuration":395,"studyType":243,"phases":4,"briefSummary":396,"conditions":397,"keywords":402,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":42},"100577616","evaluating-efficacy-and-tolerability-of-anticancer-drug-therapies-for-the-treatment-of-gynecologic-and-breast-cancers-100577616","NCT06800612","Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers","Observational Study Evaluating the Efficacy and Tolerability of Anticancer Drug Therapies Adopted for the Treatment of Gynecologic and Breast Cancers in Clinical Practice Compared with the Results of Registration Studies","Inclusion Criteria:\n\n* Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic;\n* Patients who have received treatment for breast cancer or gynecologic cancer since January 2010;\n* Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data.\n\nExclusion Criteria:\n\n* no exclusion criteria",{"count":394,"type":20},100,"1 Year","retrospective\u002Fprospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.",[398,399,400,26,401],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","Breast Cancer Metastatic","Ovarian Cancer","Endometrial Cancer",[403,404,405,406,407,408],"observational","breast cancer","gynecologic cancer","ovarian cancer","cervical carcinoma","endometrial cancer","2025-01-28",{"date":411,"type":34},"2025-01-30",{"date":413,"type":34},"2024-03-22",{"date":415,"type":20},"2030-12-31",{"name":417,"class":41},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":21,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":305},"100568808","phase-2-hpv-vaccine-imiquimod-and-metformin-combination-trial-100568808","NCT06686043","HPV Vaccine, Imiquimod, and Metformin Combination Trial","A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers","HPV-VIM","Inclusion Criteria:\n\n* Participants must have histologically confirmed locally advanced or metastatic cervical carcinoma (Stage IB2-IVB), vaginal, or vulvar carcinoma (Stage II-IVB), AND not be considered a primary surgical candidate. Patients offered neoadjuvant therapy may be enrolled if they respond and receive chemoradiation.\n* Participants must have measurable disease, per Recist criteria. See Section 12 (Measurement of Effect) for the evaluation of measurable disease. Radiological evaluation shall occur within approximately 30 days prior to enrollment initiation and start of radiation.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n* Participants must be ≥ 18 years of age\n* Participants must have adequate organ function within 28 days of registration, defined as follows: - Absolute neutrophil count ≥ 1,500\u002FµL - Platelets ≥ 100,000\u002FµL - Hemoglobin ≥ 9 g\u002FdL - Serum creatinine ≤ 1.5 x upper limit of normal (ULN) - Total bilirubin ≤ 1.5 x ULN (≤2.0 in patients with known Gilberts syndrome) OR direct bilirubin ≤ 1 x ULN - Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN\n* Participants receiving corticosteroids may continue as long as their dose is stable for at least 4 weeks prior to initiating protocol therapy.\n* Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment.\n* Female participants of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration. Females of non-childbearing potential is defined as follows (by other than medical reasons): - ≥45 years of age and has not had menses for \\>1 year, post-hysterectomy, post-bilateral oophorectomy, post external beam radiation of 6 Gy to the pelvis, or post-tubal ligation.\n* Participants must agree to not breastfeed during the study.\n* Participants must be able to understand the study procedures and agree to participate in the study by providing written informed consent\n* Participants must be eligible for chemoradiation treatment in the opinion of the treating investigator.\n* Participants who are HIV+ must have CD4 counts \\>200\u002FdL and demonstrate documented Highly active antiretroviral therapy (HAART) compliance m. Participant must have CT (chest\u002Fabdomen\u002Fpelvis) or PET-CT, within 56 days of registration.\n* Participants must be newly diagnosed.\n* Standard chemoradiation using external beam radiation therapy (EBRT) and brachytherapy is permitted for cervical or vaginal carcinoma, and chemoradiation with EBRT for vulvar carcinoma. A lesion must be readily accessible for intratumoral tumor injection.\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n\nExclusion Criteria:\n\n* Patients who are receiving any other investigational agents.\n* Patients who have untreated, new or progressive brain metastases or leptomeningeal disease.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study.\n* Patients with uncontrolled intercurrent illness.\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because cervical carcinoma or vulva carcinoma patients have undergone treatment rendering the patient infertile. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cervical carcinoma or vulva carcinoma, breastfeeding should be discontinued.","64 Years",{"count":428,"type":20},85,[170],"The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims to answer are:\n\nDoes the combination of treatments help the participant's body fight the cancer more effectively when used alongside standard therapy? What side effects or medical issues arise when using these experimental treatments? Researchers will use three experimental therapies along with the participant's standard treatment to find out if these therapies work better together than standard treatment alone.\n\nParticipants will:\n\nReceive HPV vaccinations during the 2nd and 4th week of radiation, and again at weeks 8, 10, 12, and 16 after completing radiation.\n\nHave blood samples taken, tumor cells brushed from the surface, and imiquimod cream applied during each visit.\n\nTake a daily metformin pill and apply an imiquimod suppository three times a week for two weeks after each visit.",[26,223,224,432],"HPV (Human Papillomavirus)-Associated Carcinoma",[434,376,435,436,437,438,439,440,441,442,443,444,445,446,447],"metformin","Imiquimod","Human Papillomavirus 9-valent Vaccine","Recombinant","Cytobrush","cervical cancer","vaginal cancer","vulvar cancer","chemoradiation","tumor","immunotherapy","metastatic","intratumoral","Endometrial cancer","2024-11-11",{"date":450,"type":34},"2024-11-13",{"date":452,"type":34},"2024-08-23",{"date":454,"type":20},"2028-08-23",{"name":456,"class":41},"Baylor College of Medicine",{"id":458,"slug":459,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":21,"phases":467,"briefSummary":468,"conditions":469,"keywords":477,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":42},"100533802","adaptive-radiotherapy-in-patients-with-gynecological-tumors-100533802","NCT06230549","Adaptive Radiotherapy in Patients With Gynecological Tumors","Prospective Randomized Validation of Adaptive Radiotherapy in Patients With Gynecological Tumors and Indication for Radiotherapy","ProART","Inclusion Criteria:\n\nECOG 0-1 confirmation by histophatology MR of the pelvis staging\n\nExclusion Criteria:\n\nRecurrent disease Prior Radiotherapy in pelvic region stage pM1 or cM1",{"count":466,"type":20},30,[23],"Prospective randomized evaluation of adaptive radiotherapy in the definitive radiotherapy of locally advanced gynecologic carcinoma (e.g. cervical carcinoma, endometrial carcinoma, vaginal carcinoma), in the postoperative situation or first series of external beam radiotherapy and in patients in whom radical surgery or HDR brachytherapy as dose boost is not an option.",[470,471,472,473,474,475,476,26],"Gynecological Tumor","Adaptive Radiotherapy","Radiation","Curative Treatment","Optimization","Adaptive Radiation Therapy","Image Guided Radiotherapy",[478,479,480,481,482,483,484,485],"gynecological tumor","adaptive radiotherapy","radiation","curative treatment","optimization","adaptive radiation therapy","image guided radiotherapy","Cervical carcinoma","2024-02-07",{"date":488,"type":34},"2024-02-09",{"date":490,"type":34},"2024-01-15",{"date":492,"type":20},"2026-12-15",{"name":494,"class":41},"University Hospital, Essen",{"id":496,"slug":497,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":11,"sex":77,"minAge":78,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":21,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":42},"100467416","phase-1-a-clinical-study-of-lm103-injection-in-the-treatment-of-advanced-solid-tumors-100467416","NCT05366478","A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors","A Single-Arm, Open-Label, Exploratory Study to Evaluate Safety and Efficacy of LM103 Injection in the Treatment of Advanced Solid Tumors","Inclusion Criteria:\n\n1. AJCC (V8) stage III or IV melanoma, non-small cell lung cancer, cervical cancer and other solid tumors (confirmed by histology) for which existing treatment is ineffective or without standard treatment;\n2. The patient has residual lesions that can be used for surgical resection (\\>1.5cm3) or biopsy (\\>1.5cm3) and measurable after resection for TIL collection and efficacy evaluation;\n3. Laboratory inspection index requirements:\n\n   * Blood routine: lymphocyte ratio \\> 20%; neutrophil count \\> 1.0 × 10\\^9\u002FL; white blood cells \\> 3.0 × 10\\^9\u002FL; platelets \\> 100 × 10\\^9\u002FL; hemoglobin \\> 80 g\u002F L;\n   * Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ upper limit of normal x 2.5, if there is liver metastasis ≤ upper limit of normal x 5; alkaline phosphatase (ALP) ≤ upper limit of normal x 2.5; total gallbladder Red pigment (TBIL)≤normal upper limit×1.5;\n   * Renal function: urea ≤ upper limit of normal × 1.5; creatinine (Cr) ≤ upper limit of normal × 1.5;\n4. Left ventricular ejection fraction (LVEF) ≥ 50%;\n5. ECOG physical condition is 0 or 1;\n6. The expected survival time is more than 3 months;\n\nExclusion Criteria:\n\n1. Suffering from active or previous autoimmune diseases ;\n2. Severe liver and kidney dysfunction, severe heart disease, coagulation dysfunction, and hematopoietic dysfunction;\n3. Combined with severe infection or persistent infection and cannot be effectively controlled;\n4. Central nervous system metastasis and\u002For cancerous meningitis;\n5. With uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage;\n6. Requires systemic steroid therapy;\n7. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HbcAb); positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis;",{"count":503,"type":20},15,[116],"This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.",[189,507,26],"Non Small Cell Lung Cancer","2022-08-01",{"date":510,"type":34},"2022-08-02",{"date":512,"type":34},"2022-05-30",{"date":514,"type":20},"2029-05-30",{"name":516,"class":517},"Suzhou BlueHorse Therapeutics Co., Ltd.","INDUSTRY"]